Stem Cells Turned Into Insulin Producers Offer Promise for Diabetics
WebMD News Archive
If you'd like to share your opinion on the controversy, or just have a question about diabetes, go WebMD's Diabetes board, moderated by Gloria Yee, RN, CDE. continued...
Although researchers have had some success with transplanting beta-islet cells from cadavers into people with type 1 diabetes, such cells are limited in supply and have the potential to evoke the same kind of harmful immune response from the patients as their own beta-cells do. In contrast, stem cells have the potential to provide a virtually limitless source of beta-islet cells.
But whether scientists will be able to develop human embryonic stem cells to their full potential is another question. Last week, the Bush administration ordered the National Institutes of Health to indefinitely postpone the first meeting of a committee that would review requests for government funding of research using stem cells derived from human embryos.
The move, combined with other statements and policy changes issued by Bush administration officials has scientists worried that critical medical research may be in jeopardy.
"Soon the Bush administration will decide the fate of human embryonic stem cell research at U.S. government-funded institutions, and the outcome of that decision will greatly influence the role of [embryonic stem cell] science in human developmental biology around the world," write stem cell researchers Irving Weissman, MD and David Baltimore, PhD in an accompanying editorial. "But although the forces that science brings to this field are powerful, the future of [embryonic stem cell] research will largely be determined by other interests: politics, organized religion, commerce, the legal community, and patient advocacy groups. The decision-making process needs to develop a policy that is fact-based and serves the best interests of society as well as science."
Weissman is professor of pathology and developmental biology at Stanford University. Baltimore is a Nobel Laureate and president of the California Institute of Technology, in Pasadena, Calif.
Their editorial echoes concerns expressed by another public figure. In testimony before Congress last September, actress Mary Tyler Moore, who has lived with type 1 diabetes for more than 30 years and represents the Juvenile Diabetes Foundation, spoke on behalf of the millions of people, both living and yet to be born, who could benefit from treatments developed through stem cell research. "Our obligation is to those of us who are here," she told lawmakers.